NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.380) was uploaded to the NHS England Website on Thursday 18, December 2025.
The following changes have been introduced:
Amivantamab in combination with lazertinib (AMI1)
For the first line treatment of locally advanced or metastatic non-small cell lung cancer in adults whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Avelumab in combination with axitinib (AVE3)
For use in treatment-naïve patients with advanced renal cell carcinoma where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding - column N updated
Darolutamide in combination with androgen deprivation therapy (ADT) (DARO3)
For the treatment of patients with newly diagnosed metastatic hormone-sensitive prostate cancer who are unsuitable for treatment with docetaxel where the following criteria have been met
Moved into routine commissioning - section B of list
Enfortumab vedotin in combination with pembrolizumab (ENF1)
Enfortumab vedotin with pembrolizumab for untreated, unresectable or metastatic urothelial cancer, when platinum-based chemotherapy is suitable where the following criteria have been met
Moved into routine commissioning - section B of list
Dostarlimab in combination with platinum-containing chemotherapy (carboplatin and paclitaxel) (DOS3)
For the 1st line treatment of mismatch repair proficient (pMMR) or microsatellite stable endometrial carcinoma in adult patients who have recurrent or primary advanced disease and who are not candidates for potentially curative surgery or radiotherapy or chemoradiotherapy but are eligible for systemic therapy where the following criteria have been met
Date moving into routine commissioning updated
Glofitamab in combinaton with gemcitabine and oxaliplatin (GLO2)
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B- cell lymphoma where the following criteria have been met
Date moving into routine commissioning updated
Talquetamab monotherapy (TALQ1)
For treating relapsed or refractory multiple myeloma after 3 or more treatments where the following criteria have been met
Date moving into routine commissioning updated
Glofitamab monotherapy (GLO1)
For the treatment of previously treated adult patients with diffuse large B-cell lymphoma who have received 2 or more lines of systemic therapy where the following criteria have been met
Treatment criterion (#1, 3, 4 and 7) updated; Treatment criteria (#10, 11, 12, 14, 15, 16 and 17) removed
Nivolumab (NIV8a)
Nivolumab monotherapy (with or without initial combination treatment with ipilimumab) for treating unresectable advanced malignant melanoma (form a): REGISTRATION OF START OF NIVOLUMAB MONOTHERAPY OR OF PREVIOUSLY COMMENCED AND CURRENTLY CONTINUED NIVOLUMAB MONOTHERAPY (WITHOUT INITIAL COMBINATION WITH IPILIMUMAB) OR OF PREVIOUSLY COMMENCED AND CURRENTLY CONTINUED NIVOLUMAB MONOTHERAPY AFTER INITIAL COMBINATION WITH IPILIMUMAB (clinicians starting patients on nivolumab plus ipilimumab combination treatment should only use this form after the ipilimumab part of the treatment has been completed). This form comes in 3 parts 1. The first part is for patients who are either scheduled to commence nivolumab monotherapy or who commenced and continue to receive nivolumab monotherapy or who continue to receive nivolumab monotherapy after initial combination treatment with ipilimumab. The second part of the form which must use the same unique Blueteq identifier for those benefitting patients who choose to electively discontinue nivolumab after or more years of treatment. 2. The second part (patient details will automatically entered) will only appear once the first part of the form is approved and should be completed at the time of elective discontinuation of nivolumab. The third part of the form which must use the same unique Blueteq identifier is for those patients registered as having electively and previously stopped nivolumab and whom there is disease progression for which the clinician wishes to re- commence nivolumab monotherapy. 3. The third part of the form (patient details will be automatically entered) will only appear once the second part of the form has been approved.
Treatment criterion (#9) updated
NA (NIV9)
NA
Treatment criterion (#9) updated
Olaparib in combination with hormone therapy (OLAP6)
As adjuvant treatment of high-risk HORMONE RECEPOR POSITIVE HER 2 NEGATIVE early breast cancer treated with neoadjuvant or adjuvant chemotherapy and definitive local therapy in patients with a deleterious or suspected deleterious germline BRCA mutation where the following criteria have been met
Treatment criterion (#7 and 10) updated; Treatment criteria (#11 and 14) removed
Selinexor in combination with bortezomib and dexamethasone (SELIN1)
For the treatment of multiple myeloma transplant ineligible patients who have had only 1 prior line of systemic therapy where the following criteria have been met
Treatment criterion (#5 and 13) updated; Treatment criteria (#6, 10 and 12) removed
NA (TUC1)
NA
Treatment criterion (#8, 10 and 15) updated